根据名称进行药物检索

Cimetidine Sodium Chloride 与 Dilantin

Cimetidine Sodium Chloride 与 Dilantin互相作用以及同时服用的可能性。

检测结果:

Cimetidine Sodium Chloride <> Dilantin

现实性: 22.09.2022 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

问问你的医生之前使用苯妥英一起替丁. 使用苯妥英与替丁可能增加的影响苯妥英。联系您的医生，如果你的经验抽搐的眼睛运动、口齿不清的语音、失去平衡、震颤、肌肉僵硬或软弱、恶心、呕吐的感觉头晕，昏厥，并缓慢或浅的呼吸。如果你的医生，并规定这些药物在一起，可能需要的剂量调整或特别的测试安全地使用这两种药物。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

一般避免：共同给予与替丁可能会显着增加的等离子浓度的苯妥英。拟议的机制是替丁抑制CYP450 2C9和2 19，同功负责的新陈代谢的清除苯妥英。药物动力学研究，替丁施用的剂量为1000至1200毫克/天一直是找到增加苯妥英血浆水平，具有广泛的师生变化从13%至近300％的增长和苯妥英性毒性在发展中的一些。也有罕见的报告的严重和危及生命的血小板减少，粒细胞缺乏症和皮肤反应包括有毒莱尔在患者接受苯妥英和替丁，或没有糖皮质激素。这些事件是否相关的药物动力学或药效动力学的相互作用是未知的。替丁在剂量为400毫克/天两个星期没有显着影响苯妥英血清水平或癫痫发作的频率在研究的九名患者长期苯妥英治疗。

管理：在使用的替丁通常应该避免患者在处理与苯妥英因为更安全的替代品存在，例如其他H2-受体拮抗剂或质子泵的抑制剂。这些试剂(除拉唑)已经证明了一个缺乏相互作用苯妥英药物动力学研究，只有少数情况下可疑的交互作用已经报告说，如果有的话。

来源

"Product Information. Pepcid (famotidine)." Merck & Co, Inc, West Point, PA.
Levine M, Jones MW, Sheppard I "Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin." Neurology 35 (1985): 562-5
Yue CP, Mann KS, Chan KH "Severe thrombocytopenia due to combined cimetidine and phenytoin therapy." Neurosurgery 20 (1987): 963-5
Karlstadt RG, Palmer RH, Shinn AF "Unrecognized drug interactions with famotidine and nizatidine." Arch Intern Med 151 (1991): 610, 614-5
Sambol NC, Upton RA, Chremos AN, Lin ET, Williams RL "A comparison of the influence of famotidine and cimetidine on phenytoin elimination and hepatic blood flow." Br J Clin Pharmacol 27 (1989): 83-7
Bartle WR, Walker SE, Shapero T "Dose-dependent effect of cimetidine on phenytoin kinetics." Clin Pharmacol Ther 33 (1983): 649-55
"Product Information. Aciphex (rabeprazole)" Janssen Pharmaceuticals, Titusville, NJ.
Karol MD, Locke CS, Cavanaugh JH "Lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin." J Clin Pharmacol 39 (1999): 1283-9
Andersson T, HassanAlin M, Hasselgren G, Rohss K "Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole." Clin Pharmacokinet 40 (2001): 523-37
Khan AY, Kalimuddin MN, Gorman JM "Neuropsychiatric manifestations of phenytoin toxicity in an elderly patient." J Psychiatr Pract 13 (2007): 49-54
"Product Information. Axid (nizatidine)." Lilly, Eli and Company, Indianapolis, IN.
Griffin JP "Drug interactions with agents used in the treatment of epilepsy." Adverse Drug React Toxicol Rev 15 (1996): 221-46
Phillips P, Hansky J "Phenytoin toxicity secondary to cimetidine administration." Med J Aust 141 (1984): 602
"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc, Deerfield, IL.
"Product Information. Prilosec (omeprazole)." Merck & Co, Inc, West Point, PA.
Feely J "Interaction of cimetidine with other drugs." South Med J 76 (1983): 753-8
Hetzel DJ, Bochner F, Hallpike JF, et al "Cimetidine interaction with phenytoin." Br Med J 282 (1981): 1512
"Product Information. Zantac (ranitidine)." Glaxo Wellcome, Research Triangle Park, NC.
Humphries TJ "Famotidine: a notable lack of drug interactions." Scand J Gastroenterol Suppl 134 (1987): 55-60
Tse CS, Iagmin P "Phenytoin and ranitidine interaction." Ann Intern Med 120 (1994): 892-3
Smith SR, Kendall MJ "Ranitidine versus cimetidine: a comparison of their potential to cause clinically important drug interactions." Clin Pharmacokinet 15 (1988): 44-56
Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW "Lack of pantoprazole drug interactions in man: an updated review." Int J Clin Pharmacol Ther 34 (1996): 243-62
Williams D, Kelly A, Feely J "Drug interactions avoided - a useful indicator of good prescribing practice." Br J Clin Pharmacol 49 (2000): 369-72
Rafi JA, Frazier LM, Driscoll-Bannister SM, O'Hara KA, Garnett WR, Pugh CB "Effect of over-the-counter cimetidine on phenytoin concentrations in patients with seizures." Ann Pharmacother 33 (1999): 769-74
Powell JR, Donn KH "Histamine H2-antagonist drug interactions in perspective: mechanistic concepts and clinical implications." Am J Med 77 (1984): 57-84
Bramhall D, Levine M "Possible interaction of ranitidine with phenytoin." Drug Intell Clin Pharm 22 (1988): 979-80
Bachmann KA, Sullivan TJ, Jauregui L, Reese J, Miller K, Levine L "Drug interactions of h-2-receptor antagonists." Scand J Gastroenterol 29 (1994): 14-9
Algozzine GJ, Stewart RB, Springer PK "Decreased clearance of phenytoin with cimetidine." Ann Intern Med 95 (1981): 244-5
Labenz J, Petersen KU, Rosch W, Koelz HR "A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole." Aliment Pharmacol Ther 17 (2003): 1015-1019
Sorkin EM, Darvey DL "Review of cimetidine drug interactions." Drug Intell Clin Pharm 17 (1983): 110-20
"Product Information. Protonix (pantoprazole)" Wyeth-Ayerst Laboratories, Philadelphia, PA.
Watts RW, Hetzel DJ, Bochner F, Hallpike JF, Hann CS, Shearman DJ "Lack of interaction between ranitidine and phenytoin." Br J Clin Pharmacol 15 (1983): 499-500
Neuvonen PJ, Tokola R, Kaste M "Cimetidine interaction with phenytoin." Br Med J (Clin Res Ed) 283 (1981): 501
"Product Information. Nexium (esomeprazole)" Astra-Zeneca Pharmaceuticals, Wilmington, DE.
Bachmann KA, Sullivan TJ, Jauregui L, Reese JH, Miller K, Levine L "Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity." Br J Clin Pharmacol 36 (1993): 380-2
Arbiser JL, Goldstein AM, Gordon D "Thrombocytopenia following administration of phenytoin, dexamethasone and cimetidine: a case report and a potential mechanism." J Intern Med 234 (1993): 91-4
Richards DA "Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine." J Clin Gastroenterol 5 (1983): 81-90